CapVest Partners Acquires Stada, Abandoning IPO Strategy
CapVest Partners has acquired German generics manufacturer Stada in a transaction valued at approximately 10…
Newswire
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
Esperion Therapeutics has announced that bempedoic acid has been included in the 2025 Focused Update…
Eisai Secures FDA Approval for Leqembi Autoinjector, Enabling At-Home Maintenance Dosing
The U.S. Food and Drug Administration (FDA) has granted approval for Eisai’s Leqembi IQLIK, a…
Neon Health Secures $6 Million to Enhance Access to Specialty Drugs
Neon Health, a San Francisco-based company, has successfully raised $6 million in funding aimed at…
Zenas BioPharma & Royalty Pharma Enter Obexelimab Funding Agreement for up to $300 Million
Zenas BioPharma, Inc. has entered into a significant funding agreement with Royalty Pharma plc, which…
FDA Grants RMAT Designation to ETX101 for Dravet Syndrome
Encoded Therapeutics Inc. has announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy…
Leadership Changes at Novo Nordisk and Rocket Pharma
Recent leadership transitions at Novo Nordisk and Rocket Pharma have raised significant attention within the…
Physician Enthusiasm for Novo’s Wegovy Suggests Swift Uptake in Rezdiffra-Dominated MASH Market
Recent surveys conducted by Spherix indicate a notable enthusiasm among physicians for Novo’s Wegovy, particularly…
AbbVie’s Gilgamesh Acquisition: A Strategic Shift to Single-Asset Focus
AbbVie has recently made headlines with its acquisition of Gilgamesh Pharmaceuticals, underscoring a growing trend…
Zydus Therapeutics Secures Phase 2b/3 Victory in Liver Disease: A Strategic Move Against Gilead and Ipsen
Zydus Therapeutics has achieved a significant milestone with its phase 2b/3 trial success in treating…